Kawakami H - Search Results

1

Serum HBV RNA is a predictor of early emergence of the YMDD mutant in patients treated with lamivudine.

Hatakeyama T, Noguchi C, Hiraga N, Mori N, Tsuge M, Imamura M, Takahashi S, Kawakami Y, Fujimoto Y, Ochi H, Abe H, Maekawa T, Kawakami H, Yatsuji H, Aisaka Y, Kohno H, Aimitsu S, Chayama K. Hatakeyama T, et al. Among authors: kawakami y, kawakami h. Hepatology. 2007 May;45(5):1179-86. doi: 10.1002/hep.21581. Hepatology. 2007. PMID: 17465002

2

Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients.

Tsuge M, Murakami E, Imamura M, Abe H, Miki D, Hiraga N, Takahashi S, Ochi H, Nelson Hayes C, Ginba H, Matsuyama K, Kawakami H, Chayama K. Tsuge M, et al. Among authors: kawakami h. J Gastroenterol. 2013 Oct;48(10):1188-204. doi: 10.1007/s00535-012-0737-2. Epub 2013 Feb 9. J Gastroenterol. 2013. PMID: 23397114

3

Prolonged negative HCV-RNA status led to a good outcome in chronic hepatitis C patients with genotype 1b and super-high viral load.

Kohno H, Aimitsu S, Kitamoto M, Aisaka Y, Kawakami H, Chayama K. Kohno H, et al. Among authors: kawakami h. Intervirology. 2006;49(6):362-9. doi: 10.1159/000095156. Epub 2006 Aug 21. Intervirology. 2006. PMID: 16926549 Clinical Trial.

4

Eicosapentaenoic acid could permit maintenance of the original ribavirin dose in chronic hepatitis C virus patients during the first 12 weeks of combination therapy with pegylated interferon-alpha and ribavirin. A prospective randomized controlled trial.

Takaki S, Kawakami Y, Imamura M, Aikata H, Takahashi S, Ishihara H, Tsuji K, Aimitsu S, Kawakami H, Nakanishi T, Kitamoto M, Moriya T, Satoh K, Chayama K. Takaki S, et al. Among authors: kawakami y, kawakami h. Intervirology. 2007;50(6):439-46. doi: 10.1159/000114718. Epub 2008 Feb 4. Intervirology. 2007. PMID: 18253048 Clinical Trial.

5

Prospective study of short-term peginterferon-alpha-2a monotherapy in patients who had a virological response at 2 weeks after initiation of interferon therapy.

Jeong S, Kawakami Y, Kitamoto M, Ishihara H, Tsuji K, Aimitsu S, Kawakami H, Uka K, Takaki S, Kodama H, Waki K, Imamura M, Aikata H, Takahashi S, Chayama K. Jeong S, et al. Among authors: kawakami y, kawakami h. J Gastroenterol Hepatol. 2008 Apr;23(4):541-5. doi: 10.1111/j.1440-1746.2008.05356.x. J Gastroenterol Hepatol. 2008. PMID: 18397484 Clinical Trial.

6

Dose comparison study of pegylated interferon-alpha-2b plus ribavirin in naïve Japanese patients with hepatitis C virus genotype 2: a randomized clinical trial.

Kawaoka T, Kawakami Y, Tsuji K, Ito H, Kitamoto M, Aimitsu S, Kawakami H, Jeong SC, Imamura M, Aikata H, Takahashi S, Chayama K. Kawaoka T, et al. Among authors: kawakami y, kawakami h. J Gastroenterol Hepatol. 2009 Mar;24(3):366-71. doi: 10.1111/j.1440-1746.2008.05650.x. Epub 2008 Nov 20. J Gastroenterol Hepatol. 2009. PMID: 19032459 Clinical Trial.

7

Predicting the response to 48-week combination therapy with peginterferon alpha-2b plus ribavirin from the estimated HCV RNA load index after negative serum change in genotype 1b hepatitis C patients.

Tsuji K, Kawakami Y, Aimitsu S, Kohno H, Aisaka Y, Kimura S, Nagata S, Ohgoshi H, Kitamoto M, Hidaka T, Kawakami H, Nakanishi T, Chayama K. Tsuji K, et al. Among authors: kawakami y, kawakami h. Hepatol Res. 2009 Jun;39(6):531-8. doi: 10.1111/j.1872-034X.2009.00488.x. Epub 2009 Feb 25. Hepatol Res. 2009. PMID: 19254346

8

Impact of ribavirin dose reduction on the efficacy of pegylated interferon plus ribavirin combination therapy for elderly patients infected with genotype 1b and high viral loads.

Kohno H, Kouno H, Aimitsu S, Aisaka Y, Kitamoto M, Kawakami H, Chayama K. Kohno H, et al. Among authors: kawakami h. Hepatol Res. 2011 Jul;41(7):626-34. doi: 10.1111/j.1872-034X.2011.00811.x. Hepatol Res. 2011. PMID: 21711421

9

Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C.

Fujino H, Imamura M, Nagaoki Y, Kawakami Y, Abe H, Hayes CN, Kan H, Fukuhara T, Kobayashi T, Masaki K, Ono A, Nakahara T, Honda Y, Naeshiro N, Urabe A, Yokoyama S, Miyaki D, Murakami E, Kawaoka T, Hiraga N, Tsuge M, Hiramatsu A, Hyogo H, Aikata H, Takahashi S, Miki D, Ochi H, Ohishi W, Chayama K; Hiroshima Liver Study Group. Fujino H, et al. Among authors: kawakami y. J Gastroenterol. 2014 Dec;49(12):1548-56. doi: 10.1007/s00535-013-0924-9. Epub 2013 Dec 21. J Gastroenterol. 2014. PMID: 24362944 Clinical Trial.

10

Effect of prolonged administration of pegylated interferon/ribavirin therapy in genotypes 2a and 2b: propensity score-matched analysis.

Yokoyama S, Kawakami Y, Imamura M, Hayes CN, Kohno H, Kohno H, Tsuji K, Aisaka Y, Kira S, Yamashina K, Nonaka M, Takahashi S, Moriya T, Kitamoto M, Aimitsu S, Nakanishi T, Kawakami H, Chayama K. Yokoyama S, et al. Among authors: kawakami y, kawakami h. J Gastroenterol Hepatol. 2015 Feb;30(2):337-44. doi: 10.1111/jgh.12706. J Gastroenterol Hepatol. 2015. PMID: 25091289

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,493 results

Search Page

Filters